Treatment of Pancreatic Cancer Visalia CA

Inhibiting the action of an enzyme called TAK-1 reverses pancreatic cancer resistance to chemotherapy, a finding that could lead to the development of a new way to treat the disease, researchers say. Pancreatic cancer is resistant to every currently available anti-cancer treatment.

Marty Prah
(559) 741-2870
5400 W Hillsdale Ave
Visalia, CA
Specialty
Urology

Data Provided by:
Joseph Chidi, MD
(559) 738-7549
5400 W Hillsdale Ave
Visalia, CA
Specialties
Urology
Gender
Male
Education
Medical School: Case Western Reserve Univ Sch Of Med, Cleveland Oh 44106
Graduation Year: 1978

Data Provided by:
Tu Hi Hong, MD
(559) 686-0690
919 E Merritt Ave
Tulare, CA
Specialties
Urology
Gender
Male
Education
Medical School: Creighton Univ Sch Of Med, Omaha Ne 68178
Graduation Year: 1977
Hospital
Hospital: Tulare District Hosp, Tulare, Ca

Data Provided by:
Dean James Limbert, MD
(559) 582-0453
900 N Douty St Ste A
Hanford, CA
Specialties
Urology
Gender
Male
Languages
French, Greek
Education
Medical School: Northwestern Univ Med Sch, Chicago Il 60611
Graduation Year: 1961
Hospital
Hospital: Hanford Comm Med Ctr, Hanford, Ca; Tulare District Hosp, Tulare, Ca

Data Provided by:
Fightlin, Richard S, Md - Griffith Urology Clinic
(559) 582-4245
1004 N Douty St
Hanford, CA

Data Provided by:
Joseph Chidi
(559) 738-7500
5400 W Hillsdale Ave
Visalia, CA
Specialty
Urology

Data Provided by:
Tu-Hi Hong
(559) 686-0690
919 E Merritt Ave
Tulare, CA
Specialty
Urology

Data Provided by:
Lyle D Griffith, MD
(559) 582-4245
1004 N Douty St
Hanford, CA
Specialties
Urology
Gender
Male
Education
Medical School: Univ Of Wa Sch Of Med, Seattle Wa 98195
Graduation Year: 1968

Data Provided by:
Jeffrey William Csiszar, MD
(559) 587-0330
804 W 7th St
Hanford, CA
Specialties
Urology
Gender
Male
Education
Medical School: Univ Of Southern Ca Sch Of Med, Los Angeles Ca 90033
Graduation Year: 1989
Hospital
Hospital: Hanford Comm Med Ctr, Hanford, Ca; Kaweah Delta District Hosp, Visalia, Ca

Data Provided by:
Gary Bellman
(818) 703-9500
23101 Sherman Place
West Hills, CA
Business
Gary Bellman MD
Specialties
Urology
Additional Information
Languages Spoken: English,Hebrew,French

Data Provided by:
Data Provided by:

Treatment of Pancreatic Cancer

Provided By:

FRIDAY, Sept. 25 (HealthDay News) -- Inhibiting the action of an enzyme called TAK-1 reverses pancreatic cancer resistance to chemotherapy, a finding that could lead to the development of a new way to treat the disease, researchers say.

Pancreatic cancer is resistant to every currently available anti-cancer treatment.

"During the past few years we have been studying the role played by a cytokine or regulatory protein called transforming growth factor-beta [TGFbeta] in the development of pancreatic cancer. Recently we focused our attention on a unique enzyme activated by TGFbeta, TAK-1, as a mediator for this extreme drug resistance" in pancreatic cancer, study author Dr. Davide Melisi said in a news release from the European Cancer Organization.

He and his colleagues developed a TAK-1 inhibitor and tested it on its own and in combination with the anti-cancer drugs gemcitabine, oxaliplatin and SN-38 (a metabolite of the anti-cancer drug irinotecan) in pancreatic cancer cell lines. They also tested the TAK-1 inhibitor combined with gemcitabine against pancreatic cancer in mice.

"The use of this TAK-1 inhibitor increased the sensitivity of pancreatic cells to all three chemotherapeutic drugs," Melisi said.

"By combining it with classic anti-cancer drugs, we were able to use doses of drugs up to 70 times lower in comparison with the control to kill the same number of cancer cells. In mice, we were able to reduce significantly the tumor volume, to prolong the mice survival, and to reduce the toxicity by combining the TAK-1 inhibitor with very low doses of a classic chemotherapeutic drug, gemcitabine, that would have been ineffective otherwise," Melisi added.

The study was scheduled for presentation Sept. 24 at the joint meeting of the European Cancer Organization and the European Society for Medical Oncology in Berlin.

"This is the first time that TAK-1 has been indicated as a relevant target for the treatment of a solid tumor and that it is a valid approach to reverting the intrinsic drug resistance of pancreatic cancer," Melisi stated. "The TAK-1 inhibitor used in this study is an exciting drug that warrants further development for the treatment of pancreatic cancer."

More information

The American Cancer Society has more about pancreatic cancer.

SOURCE: European Cancer Organization, news release, Sept. 24, 2009

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com